Visual inspection of injectable products has always been one of the most challenging parts of sterile manufacturing. Unlike purely instrument-driven quality checks, it relies heavily on human inspectors, their training, and the tools used to support them. Because of this, FDA investigators consistently find gaps during inspections, and many of these observations end up as Form 483s.
What is striking is that the same themes appear again and again across companies: questions about inspector qualification, missing or incomplete defect kits, lack of scientific rationale in SOPs, and inadequate controls for human fatigue. These aren’t minor oversights. They go to the very heart of compliance, and ultimately, patient safety.
Let’s take a closer look at some of the most common FDA findings, and then explore what a sound remediation strategy might look like.
Qualification Failures
One of the more concerning observations comes when inspectors who were supposedly “qualified” fail re-testing during an FDA inspection. In several cases, investigators randomly selected a trained inspector, gave them a qualification kit, and watched them miss critical defects.
This immediately raises doubts: Were inspectors qualified rigorously enough in the first place? Was the qualification system designed to truly measure competence, or just to “check the box”?
Training Not Verified for Critical Defects
Another recurring theme is training that looks good on paper but doesn’t stand up in practice. Companies often rely on pictures or classroom sessions, but USP <1790> is clear — inspectors must be tested with actual defect samples, and that testing must cover all critical defect types.
FDA has flagged cases where new defect types were added to the inspection SOP, but inspectors were only trained with pictures and never re-qualified with actual samples. This leaves a dangerous gap between written procedures and demonstrated competence.
Fatigue and Time Tracking Gaps
Visual inspection is not only about what defects are in the vial — it’s also about the person doing the inspection. FDA inspectors have noted that some facilities do not evaluate fatigue at all, nor do they have any system for tracking how long inspectors spend examining each unit.
This is risky. Fatigue is a well-recognized source of variability, and USP <1790> as well as EU GMP Annex 1 recommend clear controls around inspection time, rest periods, and periodic requalification to account for human limitations. Without these safeguards, the reliability of inspection data is undermined. The amount of time spent by Inspectors examining all the products need to be consistent
Incomplete or Invalid Defect Kits
Defect kits are the foundation of inspector training and qualification. Yet, many 483s show that kits are missing critical defect types or do not include small, low-contrast particles that are particularly Difficult to Detect.
USP <790> emphasizes that visual inspection must be capable of detecting relevant particulate matter. If the defect kit doesn’t actually represent the range of defects inspectors are expected to catch, the qualification becomes meaningless.
Lack of Justification in SOPs
FDA also frequently challenges how companies classify defects as “critical,” “major,” or “minor.” In some cases, black particles — typically considered critical — were reclassified as “major” without any documented scientific rationale.
This kind of reclassification raises red flags. 21 CFR 211.100(a) requires procedures to be based on sound science, and USP <1790> specifically calls for a risk-based, well-documented approach to defect classification. Without this, SOPs lose credibility, and inspectors lose confidence.
Training & Qualification Gaps
Finally, there are broader concerns around whether employees are adequately trained and experienced for their assigned roles. Visual inspection is often treated as a simple, mechanical task, but FDA’s repeated findings suggest otherwise. Training programs that don’t align with qualification test kits — or that fail to cover all critical defects — set inspectors up for failure and invite regulatory scrutiny.
How to Approach Remediation
Addressing these issues is not about quick fixes. It requires a structured, thoughtful approach that combines regulatory expectations with practical implementation. Here are some principles that can guide remediation:
- Rebuild the Defect Classification System
Every classification of critical, major, and minor defects should be backed by documented, scientific rationale. This means revisiting SOPs, aligning them with USP <1790>, USP <790>, and EU GMP Annex 1, and ensuring risk-based justification is clear and defensible. - Upgrade Training and Qualification
Inspectors should practice and be qualified using actual defect kits that contain the full range of critical defects. Qualification should be a living process, repeated periodically, not a one-time event. - Strengthen Defect Kits
Kits should be comprehensive, representative, and verifiable. They must cover small and low-contrast particles, as well as defects known to be difficult to detect. Certification, traceability, and controlled recertification schedules add credibility during audits. - Introduce Fatigue and Time Controls
Establish clear guidelines for inspection duration and mandatory breaks. Track inspection times electronically to ensure consistency across inspectors. Build fatigue evaluations into the qualification process, in line with USP <1790> recommendations. These are easily solved for by introduction FDA compliant Manual Visual Inspection Booth. - Conduct Periodic Gap Assessments
Don’t wait for the next FDA inspection to uncover weaknesses. Regular internal audits and mock inspections, specifically focused on visual inspection practices, can highlight gaps early and provide opportunities to address them proactively.
Final Word
The FDA’s expectations for visual inspection are well-defined across USP <790>, USP <1790>, Annex 1 and all global regulatory standards. The challenge is not in understanding what regulators want — it is in consistently embedding those expectations into day-to-day practice.
Remediation, then, is not just about avoiding the next 483. It’s about building a culture of scientific rigor where SOPs, defect kits, training, and inspector performance are aligned and auditable. When this happens, compliance becomes sustainable — and the focus shifts back to what matters most: protecting patients.